I-Hophargene Biopharma iphumelele i "2022 China Dicodsicine Chain Priing Rath" elona candelo liphambili kwi-Services entsha yeRhafu

NgoDisemba 30, 2022, u "2022 ChinasmoceOutical Shriveges" I-Jiangsu Hillgene biopharguorutical Co., i-LTD. ngempumelelo i-HOGY HORVO "kwaye yamkelwa njengeyona ndlela" ye-2022. "

Olu luhlu lwenziwe kusetyenziswa idatha kwimithombo eyahlukeneyo, kubandakanya nophando olutsha lweziyobisi kunye nedatha ekwabeka iliso kwi-Deplopy, iZiko ledatha leziyobisi elibanzi leziyobisi. IPHULO LOKUTHENGA "IPROPE YESIBONELELO ENGCWELE YOKUGQIBELA" INKQUBO YOKWENZIWAYO, Iikhrayitheriya zovavanyo zasungulwa kwimilinganiselo ye-12, enje ngeethagethi zeNoves, inkqubela phambili kwezobuchwephesha, kunye nophando nophuhliso lotyalo-mali. Iphaneli yeengcali kunye neengcali zaqhuba iinkomfa zevidiyo, ukuvota kwi-Intanethi, kwaye zinezintanda zovavanyo ezibanzi zokukhetha amabhaso amabhaso, amabhaso e-Kunpeng, kunye namabhaso ehashe. Olu luhlu lube libhaso elibonakalayo kwicandelo lezinto ezintsha kunye nenguqu kumzi-mveliso we-biophamarmical.

As the first company in the country to be granted the "Drug Production Permit" for the full-process entrusted production of CAR-T cell therapy drugs, Hillgene Biopharma is dedicated to providing its customers with comprehensive, quality-assured, and three-dimensional full-process Cell and Gene Therapy Contract Development and Manufacturing Organization (CQDMO) services.

Eli bhaso alichazi nje kuphela ingqalelo i-Rillgene Billgene Biopharmative Persoctions kodwa ikwasebenza njengenkuthazo yokuqhubela phambili kwicandelo le-CQDMO. Kwixa elizayo, induli ye-biopharma iya kuqhubeka nokumisela imigangatho yemizi-mveliso, ifanelekile iimodeli zenkonzo, ukukhawulezisa uphuhliso lwamachiza okunyanga, kwaye utyhala ngaphezulu kwezi ntengiso.

IXESHA LOKUQALA: 2023 - I-02 - 17 00:00:00